
Sanofi has paid an initial $300 million for collaboration and license agreement to develop sotagliflozin, one of a newer class …
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals

